standard of care and progress with parp inhibitors for ovarian cancer
Published 5 years ago • 125 plays • Length 6:14Download video MP4
Download video MP3
Similar videos
-
8:33
the standard of care and progress so far with parp inhibitors for ovarian cancer
-
2:58
standard of care updates in ovarian cancer: parp inhibitors
-
3:45
parp inhibitors for ovarian cancer
-
1:38
updates in parp inhibition for ovarian cancer
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
2:38
assessing the role of parp inhibitors and immunotherapy in ovarian cancer
-
4:06
the promise of parp inhibitors and their emerging role in ovarian cancer
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
0:46
parp inhibitor rechallenging in ovarian cancer
-
6:25
combinations with parp inhibitors for ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
0:45
evaluating future use of parp inhibitors in neoadjuvant therapy for ovarian cancer
-
18:37
ongoing clinical trials with parp inhibitors in ovarian cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
6:43
sequencing parp inhibitors in advanced ovarian cancer
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia
-
8:41
parp inhibitors for ovarian cancer: use of olaparib
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
1:24
innovations in ovarian cancer treatment: parp inhibitors